Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has granted a rolling new drug application (NDA) submission for suzetrigine (formerly known as VX-548) in moderate-to-severe acute pain. The company has already initiated the rolling submission process and is on track to complete the NDA submission in the second quarter of 2024.Suzetrigine is an investigational orally administered selective NaV1.8 pain signal inhibitor. The rolling NDA submission is supported by encouraging results from the c ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $394.17, reflecting a -0.8% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. Elsewhere, the Dow gained 0.41%, while the tech-heavy Nasdaq added 0.12%.The drugmaker's stock has dropped by 3.41% in the past month, exceeding the Medical sector's loss of 5.81% and lagging the S&P 500's loss of 0.9%.Investors will be eagerly watching for the perfor ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) .Vertex currently has an average brokerage recommendation (ABR) o ...

Vertex just laid claim to an asset that might be very valuable.Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (VRTX -0.92%) announced it would purchase Alpine Immune Sciences (ALPN -0.05%) for $4.9 billion in cash in a deal that's set to close before the end of this quarter. The prized asset that Vertex will gain as part of this purchase is ALPN-303, a potential autoimmune treatment that's in phase 2 clinical trials.But there's a lot more to the deal's potential value ...

Proactive团队报道 - Emily Jarvie在澳大利亚和加拿大从事政治新闻和商业报道[1] - Proactive的新闻团队遍布全球金融和投资中心[2] Proactive团队关注领域 - Proactive团队专注于中小市值市场和蓝筹公司等投资故事[3] - Proactive团队涵盖生物技术、矿业、能源、数字货币和新兴技术等领域[4]

The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?Vertex Pharmaceuticals (VRTX -1.71%) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an investment? Is it time for investors to consider other stocks instead, or can Vertex still be a good buy right now?Let's dive in and take a look.Why investor ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最新收盘价为$397.58，较前一天下跌了1.71%[1] 财报预测 - Vertex Pharmaceuticals计划于2024年5月6日公布财报，预计每股收益将增长33.44%[3] - Zacks Consensus Estimates预测Vertex Pharmaceuticals整个财年的每股收益为$16.79，营收为106.9亿美元[4]

This innovative machine rolls on.Biotech giant Vertex Pharmaceuticals (VRTX -0.82%) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive phase 3 results for exciting candidates.The drugmaker isn't stopping. Vertex is moving forward with another investigational medicine that could become a big deal somewhere down the road. Let's find out what it is and what it could mean for investors.Straight out of the playbookFirst, l ...

Vertex Pharmaceuticals (VRTX) initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting kidney function.This phase III portion will evaluate a 45 mg oral dose of Vertex’s drug, on top of standard of care, in AMKD patients, compared with placebo. Management also expanded the study to include adolescents aged 10 and older with AMKD. Previously, the AMPLITUDE study only enrolled adults with the diseas ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $420.48, with a +0.59% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%.Prior to today's trading, shares of the drugmaker had lost 3.41% over the past month. This has lagged the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.The investment community will be c ...